Efficacy, safety, and tolerability of plecanatide in patients with irritable bowel syndrome with constipation: results of two phase 3 randomized clinical trials
Authors:
- 1 May 2018
- journal article
- research article
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
- Vol. 113 (5) , 735-745
Abstract
OBJECTIVES:Two identical, phase 3, randomized, double-blind, placebo-controlled trials evaluated the efficacy and safety of plecanatide in patients with irritable bowel syndrome with constipation (IBS-C).METHODS:Adults meeting Rome III criteria for IBS-C were randomized (1:1:1) to placebo or plecanaKeywords
This publication has 30 references indexed in Scilit:
- Emerging receptor target in the pharmacotherapy of irritable bowel syndrome with constipationExpert Review of Gastroenterology & Hepatology, 2013
- Global Prevalence of and Risk Factors for Irritable Bowel Syndrome: A Meta-analysisClinical Gastroenterology and Hepatology, 2012
- Intestinal barrier function in health and gastrointestinal diseaseNeurogastroenterology & Motility, 2012
- Health-related quality of life, work productivity and health care resource use associated with constipation predominant irritable bowel syndromeCurrent Medical Research and Opinion, 2011
- Loss of Guanylyl Cyclase C (GCC) Signaling Leads to Dysfunctional Intestinal BarrierPLOS ONE, 2011
- Uroguanylin Regulates Net Fluid Secretion via the NHE2 Isoform of the Na+/H+ Exchanger in an Intestinal Cellular ModelCellular Physiology and Biochemistry, 2011
- Linaclotide, through activation of guanylate cyclase C, acts locally in the gastrointestinal tract to elicit enhanced intestinal secretion and transitEuropean Journal of Pharmacology, 2010
- International Survey of Patients With IBSJournal of Clinical Gastroenterology, 2009
- Functional Bowel DisordersGastroenterology, 2006
- The usual medical care for irritable bowel syndromeAlimentary Pharmacology & Therapeutics, 2004